Display options
Cite
Udofot O, Jaruszewski K, Spencer S, et al. Development of a novel approach to enhance the solubility of ftibamzone formulation. Integr Mol Med. 2014;1(3):61-66doi: 10.15761/IMM.1000111.
Udofot, O., Jaruszewski, K., Spencer, S., & Agyare, E. (2014). Development of a novel approach to enhance the solubility of ftibamzone formulation. Integrative molecular medicine, 1(3), 61-66. https://doi.org/10.15761/IMM.1000111
Udofot, Ofonime, et al. "Development of a novel approach to enhance the solubility of ftibamzone formulation." Integrative molecular medicine vol. 1,3 (2014): 61-66. doi: https://doi.org/10.15761/IMM.1000111
Udofot O, Jaruszewski K, Spencer S, Agyare E. Development of a novel approach to enhance the solubility of ftibamzone formulation. Integr Mol Med. 2014;1(3):61-66. doi: 10.15761/IMM.1000111. PMID: 26120473; PMCID: PMC4479287.
Copy Download .nbib Format: NLM
Share it on

Integr Mol Med. 2014;1(3):61-66. doi: 10.15761/IMM.1000111.

Development of a novel approach to enhance the solubility of ftibamzone formulation.

Integrative molecular medicine

Ofonime Udofot, Kristen Jaruszewski, Shawn Spencer, Edward Agyare

Affiliations

  1. Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A and M University, Tallahassee, FL, USA.
  2. Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A and M University, Tallahassee, FL, USA ; The University Texas, MD Anderson Cancer Center, Houston, TX, USA.

PMID: 26120473 PMCID: PMC4479287 DOI: 10.15761/IMM.1000111

Abstract

Ftibamzone (FBZ) is known to be effective against herpes simplex virus that causes genital herpes but poor solubility of FBZ has reduced its therapeutic efficacy. We investigated water-soluble complexes of various nanoparticles with FBZ to improve its solubility as well as increase its absorption. Using phase-solubility technique, we measured formation constant (K

Keywords: ftibamzone; genital herpes; nanoparticles; simplex herpes virus; solubility

References

  1. J Pharm Sci. 1999 Sep;88(9):945-7 - PubMed
  2. Bioorg Med Chem. 2008 May 1;16(9):5189-98 - PubMed
  3. J Pharm Sci. 1977 Jul;66(7):994-7 - PubMed
  4. J Pharm Sci. 1999 May;88(5):507-9 - PubMed
  5. Chem Pharm Bull (Tokyo). 2011;59(8):1016-9 - PubMed
  6. Antimicrob Agents Chemother. 1981 Apr;19(4):682-5 - PubMed
  7. J Clin Virol. 2008 Oct;43(2):190-5 - PubMed
  8. Lancet. 2007 Dec 22;370(9605):2127-37 - PubMed
  9. J Pharm Sci. 2005 May;94(5):983-93 - PubMed
  10. Colloids Surf B Biointerfaces. 2011 Mar;83(1):103-7 - PubMed
  11. Toxicol Appl Pharmacol. 2004 Jun 1;197(2):107-12 - PubMed
  12. J Colloid Interface Sci. 2010 Nov 1;351(1):19-29 - PubMed
  13. Adv Drug Deliv Rev. 2007 Jul 30;59(7):546-67 - PubMed
  14. Biomaterials. 2014 Feb;35(6):1967-76 - PubMed
  15. J Pharm Sci. 2002 Nov;91(11):2307-16 - PubMed
  16. Zhonghua Yi Xue Za Zhi. 1985 Oct;65(10):587-9 - PubMed
  17. Yao Xue Xue Bao. 1986 Apr;21(4):252-5 - PubMed
  18. Nanomedicine. 2012 Feb;8(2):250-60 - PubMed
  19. Antiviral Res. 1999 May;42(1):1-14 - PubMed
  20. Clin Diagn Lab Immunol. 1997 Jul;4(4):465-8 - PubMed
  21. J Pharm Biomed Anal. 2003 Mar 26;31(4):775-83 - PubMed
  22. Drug Dev Ind Pharm. 2007 Jul;33(7):767-74 - PubMed
  23. Eur J Pharm Sci. 2009 Jun 28;37(3-4):223-30 - PubMed
  24. Pharmacol Ther. 1981;12(2):255-97 - PubMed
  25. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5087-91 - PubMed

Publication Types

Grant support